期刊
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
卷 16, 期 3, 页码 122-128出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2015.12.008
关键词
Combined modality therapy; Early stage; Non-Hodgkin lymphoma; Radiotherapy; Survival
资金
- National Cancer Institute, National Institutes of Health [Cancer Center Support (Core) Grant] [CA016672]
Plasmablastic lymphoma is a rare, aggressive subtype of non-Hodgkin lymphoma initially described in patients infected with human immunodeficiency virus (HIV) but recently recognized in HIV-negative individuals as well. Disease most often presents as advanced, with a median overall survival time of 14 months. We examined outcomes of patients with stage I/II disease, most of whom received combined-modality therapy. Treatment was well tolerated, and long-term survival was achieved. Background: Plasmablastic lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma. We sought to assess the treatment outcomes after combined-modality therapy for early-stage PBL. Materials and Methods: We retropectively reviewed the outcomes of 10 consecutive patients diagnosed with stage I-II PBL from February 2001 to December 2013 at a single institution. The baseline clinical characteristics, treatment modalities, overall outcomes, and treatment-related toxicity were assessed. Results: The median age at diagnosis was 50.5 years. All patients had extranodal disease; 2 were positive for human immunodeficiency virus. Seven patients received hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone)-based chemotherapy, 2 received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and 1 received dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Radiotherapy (RT) was administered after a complete response to chemotherapy in 7 patients and a partial response in 1 patient. At a median follow-up period of 42 months, the estimated 2-year progression-free and overall survival rates were 90% and 100%, respectively. Conclusion: PBL can be successfully treated with aggressive chemotherapy followed by RT. The treatment was well tolerated and can result in long-term survival for patients with limited-stage disease. (C) 2016 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据